Blockbuster weight loss drugs like Wegovy and Zepbound have surged in popularity, but high prices have left them out of reach ...

The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity ...

State Medicaid programs already are allowed to offer GLP-1 drugs for weight loss, but only 13 state programs currently do so.

A five-year experiment aims to open access to blockbuster GLP‑1 drugs for obesity, something advocates have pushed for years.

TAMPA, FL / ACCESS Newswire / July 29, 2025 / The explosive popularity of GLP-1 weight-loss medications such as Ozempic®, ...

Medicare and Medicaid could expand coverage of GLP-1 drugs, such as Ozempic and Wegovy, and pay for patients’ use of the ...

Ozempic has always come with side effects. The latest reported by users? Thinning hair and muscle loss. Experts break down ...

Cosmetic surgeons are seeing a new wave of patients seeking treatment for "Ozempic face" - the sagging, hollow appearance ...

What happens when you stop taking Ozempic®? There’s no one-size-fits-all answer to this question. When you stop taking ...

Entrepreneurship raises your risk of obesity, but small changes to your diet can have similar affects to new weight-loss ...

Novo Nordisk has struggled to adapt to very high demand and a market where celebrities are more influential than doctors.